Multimedia

Multimedia

Sound Bites and exclusive interviews with researchers, commentators, and experts in the field.

video

Sherrill J. Schlicter, MD: Prolonging Platelet Shelf-Life With DMSO

Transfusion with cryopreserved platelets may offer superior bleeding control for thrombocytopenic patients. Dr. Schlicter shares results from a phase I study, and gives a...
video

Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients

Dr. Pipe, a speaker in the Special Education Session on Newly Approved Drugs, reviews what clinicians need to know about coagulation factor IX (recombinant)/antihemophilic...
video

Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML

Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
video

Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients

Dr. Jackson shares results from the phase III Myeloma XI study, which compared patients treated with lenalidomide maintenance therapy or no maintenance therapy in...
video

Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma

Dr. Cohen talks about the potential for bringing CAR T-cell therapy to heavily-pretreated myeloma patients, as well as the potential toxicities.
video

Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?

The first-in-class humanized monoclonal antibody crizanlizumab reduced the rate of sickle cell-related pain crises, compared with placebo. Dr. Ataga discusses results of the SUSTAIN...
video

Robert E. Marcus, MD: GALLIUM Study of Obinutuzumab in Untreated Follicular Lymphoma

Results from the GALLIUM trial, which were presented as a Late-Breaking Abstract at the 2016 ASH Annual Meeting, showed that first-line treatment with obinutuzumab...
video

Sattva S. Neelapu, MD: Encouraging Results for CAR T-Cells in Refractory DLBCL

Dr. Neelapu shares results from the ZUMA-1 trial, in which treatment with anti-CD19 CAR T-cell therapy led to complete remissions in patients with relapsed...
video

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

For patients who experience graft-versus-host disease after transplant and do not respond to corticosteroids, ibrutunib leads to a high, durable response rate, according to...
video

John Mascarenhas, MD, MS: Continuing to Evaluate Pacritinib for Myelofibrosis

Dr. Mascharenhas discusses results from the randomized phase III PERSIST-2 trial of the JAK2 inhibitor pacritinib in patients with myelofibrosis and thrombocytopenia, which was...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title